论文部分内容阅读
目的观察贝那普利、阿托伐他汀钙联合疗法在糖尿病肾病中的治疗效果,并对联合疗法临床应用价值进行分析。方法 90例糖尿病肾病患者根据意愿分为观察组与对照组,各45例。观察组采用贝那普利+阿托伐他汀钙联合疗法进行治疗,对照组单纯给予贝那普利治疗,对两组患者临床治疗情况进行比较。结果观察组临床治疗总有效率为88.89%,明显高于对照组的62.22%,差异具有统计学意义(P<0.05)。观察组不良反应发生率为6.67%,显著低于对照组的22.22%,差异具有统计学意义(P<0.05)。结论贝那普利、阿托伐他汀钙联合疗法治疗糖尿病肾病,临床效果明显,且具有用药安全性,值得临床推广。
Objective To observe the therapeutic effect of benazepril combined with atorvastatin calcium in diabetic nephropathy and to analyze the clinical value of combination therapy. Methods Ninety patients with diabetic nephropathy were divided into observation group and control group according to their wishes, each with 45 cases. The observation group was treated with benazepril combined with atorvastatin calcium. The control group was treated with benazepril alone, and the clinical treatment of the two groups was compared. Results The total effective rate of clinical observation in observation group was 88.89%, which was significantly higher than that in control group (62.22%), the difference was statistically significant (P <0.05). The incidence of adverse reactions in the observation group was 6.67%, which was significantly lower than that in the control group (22.22%), the difference was statistically significant (P <0.05). Conclusion The combination of benazepril and atorvastatin calcium in the treatment of diabetic nephropathy has obvious clinical effect and safety of medication, which is worthy of clinical promotion.